UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer

Oncogene, 2006-05, Vol.25 (21), p.2987-2998

2006

Volltextzugriff (PDF)

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway

Oncogene, 2007-11, Vol.26 (51), p.7240-7250

2007

Volltextzugriff (PDF)

Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells

Leukemia, 1999-07, Vol.13 (7), p.1028-1036

1999

Volltextzugriff (PDF)

Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion

Oncogene, 2002-11, Vol.21 (54), p.8272-8281

2002

Volltextzugriff (PDF)

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer

Clinical cancer research, 1999-09, Vol.5 (9), p.2366-2373

1999

Volltextzugriff (PDF)

Behavioral Consultation in Applied Settings: An Individual Guide

1, 1990

Volltextzugriff (PDF)

Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833

Journal of clinical oncology, 2001-02, Vol.19 (3), p.832-842

2001

Volltextzugriff (PDF)

Pharmacokinetics of thalidomide in an elderly prostate cancer population

Journal of pharmaceutical sciences, 1999-01, Vol.88 (1), p.121-125

1999

Volltextzugriff (PDF)

p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion

Oncogene, 2003-07, Vol.22 (31), p.4841-4850

2003

Volltextzugriff (PDF)

848PDPhase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination of tumour-infiltrating immune cells and fecal microbiota

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

The American journal of medicine, 1995-04, Vol.98 (4), p.412-414

1995

Volltextzugriff (PDF)

Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification

Prostate cancer and prostatic diseases, 2006-12, Vol.9 (4), p.379-391

2006

Volltextzugriff (PDF)

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer

Journal of clinical oncology, 1997-04, Vol.15 (4), p.1470-1477

1997

Volltextzugriff (PDF)

Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

Cancer, 1995-08, Vol.76 (3), p.453-462

1995

Volltextzugriff (PDF)

Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial

Cancer prevention research (Philadelphia, Pa.), 2012-02, Vol.5 (2), p.309-319

2012

Volltextzugriff (PDF)

Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (8), p.3470-3478

2005

Volltextzugriff (PDF)

Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells

Prostate cancer and prostatic diseases, 2001-01, Vol.4 (2), p.81-91

2001

Volltextzugriff (PDF)

Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1)

The Prostate, 1998-09, Vol.37 (1), p.51-59

1998

Volltextzugriff (PDF)

Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer

Urology (Ridgewood, N.J.), 2001-04, Vol.57 (4), p.77-80

2001

Volltextzugriff (PDF)

Chemoprevention in prostate cancer

Cancer treatment and research, 2001, Vol.106, p.103

2001

Volltextzugriff (PDF)

Effect of a soy isoflavone intervention on estrogen-related gene expression in the healthy high risk breast

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.635-635

2011

Volltextzugriff (PDF)

Acute renal toxicity associated with suramin in the treatment of prostate cancer

Cancer, 1994-09, Vol.74 (5), p.1612-1614

1994

Volltextzugriff (PDF)

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal

Clinical cancer research, 1998-01, Vol.4 (1), p.37-44

1998

Volltextzugriff (PDF)

Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation

Clinical & experimental metastasis, 2000, Vol.18 (3), p.203-212

2000

Volltextzugriff (PDF)

In vitro models of prostate apoptosis: Clusterin as an antiapoptotic mediator

The Prostate, 2000, Vol.45 (S9), p.21-24

2000

Volltextzugriff (PDF)

1 – 25 von 789

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(465)
Mit Volltextzugriff
(606)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway

Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells

Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer

Behavioral Consultation in Applied Settings: An Individual Guide

Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833

Pharmacokinetics of thalidomide in an elderly prostate cancer population

p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion

848PDPhase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination of tumour-infiltrating immune cells and fecal microbiota

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer

Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial

Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells

Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells

Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1)

Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer

Chemoprevention in prostate cancer

Effect of a soy isoflavone intervention on estrogen-related gene expression in the healthy high risk breast

Acute renal toxicity associated with suramin in the treatment of prostate cancer

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal

Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation

In vitro models of prostate apoptosis: Clusterin as an antiapoptotic mediator

Suchergebnisse filtern